3 completed, 1 active not recruiting, 1 terminated. 5 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 3, Active not recruiting 1, Terminated 1 |
| Phase 2 | 3 | Completed 2, Terminated 1 |
Follow Antiemetics: new trials by email Literature Review of Antiemetics trials Research Report on Antiemetics
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer. [68Ga]Ga-PSMA-11, [68Ga]GA-DOTA-TATE, [68Ga]Ga-NeoB - Metastatic Neuroendocrine Prostate Cancer | Phase 1 | Active not recruiting | Novartis Pharmaceuticals | 31 | 2024-07-29 | 2026-10-15 |
| Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors (MK-1200-002) MK-1200, Antiemetic - Advanced Solid Tumors | Phase 1 / Phase 2 | Completed | Merck Sharp & Dohme LLC | 13 | 2024-02-28 | 2026-06-05 |
| CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies CD19/CD22 CAR T-Cells, Fludarabine, Cyclophosphamide - Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, B Cell | Phase 1 | Completed | National Cancer Institute (NCI) | 54 | 2018-03-26 | 2025-06-04 |
| Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma Selinexor, Melphalan, Dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 22 | 2017-07-20 | 2022-11-04 |
| Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs Satoreotide tetraxetan, Amino acid solution, Antiemetic - Neuroendocrine Tumors | Phase 1 / Phase 2 | Terminated | Ipsen | 40 | 2017-03-06 | 2023-07-19 |
Burkitt Lymphoma (1) · Leukemia, B-Cell (1) · Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoma, Non-Hodgkin (1) · Multiple Myeloma (1) · Neuroendocrine Tumors (1) · Philadelphia Chromosome (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
H. Lee Moffitt Cancer Center and Research Institute (1) · Ipsen (1) · Merck Sharp & Dohme LLC (1) · National Cancer Institute (NCI) (1) · Novartis Pharmaceuticals (1)
United States (5) · Australia (2) · France (2) · United Kingdom (2) · Austria (1) · Canada (1) · Chile (1) · China (1) · Denmark (1) · Germany (1) · Israel (1) · South Korea (1) · Spain (1) · Switzerland (1)
Nirali N Shah, M.D. (1) · Taiga Nishihori, M.D. (1)
PMID 33023948, PMID 34687939, PMID 34889384, PMID 35605184, PMID 37486616, PMID 37721581, PMID 38376944, PMID 38528164, PMID 42248607
2023 (2), 2015 (1)